$5.580
-0.156 (-2.79%)收盤時
- High
- 5.780
- Open
- 5.670
- VWAP
- 5.59
- Vol
- 240.87K
- Mkt Cap
- 66.52M
- Low
- 5.400
- Amount
- 1.35M
- EV/EBITDA, TTM
- 0.00
AN2 Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.
估值指標
事件時間軸
資訊
5.008-24NASDAQ.COMAN2 Therapeutics Appoints New Chief Medical Officer
9.508-12NASDAQ.COMAN2 Therapeutics Reports Wider Q2 Loss Amid Increased R&D Spending
7.007-20PRnewswireAN2 Therapeutics Under Investigation by Shareholders
9.006-04seekingalphaAN2 Therapeutics Advances Chagas Disease Therapy
9.006-04NewsfilterAN2 Therapeutics Reports Positive Results for Chagas Disease Treatment
ANTX FAQ — answered by Alphio AI
AN2 Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。